Apyx Medical (APYX) Short term Debt (2010 - 2023)

Apyx Medical (APYX) posted Short term Debt of $8.9 million for Q2 2023, up 1.3% on a QoQ basis from $8.8 million in Q1 2023.

Apyx Medical (APYX) Short term Debt (2010 - 2023) Analysis & Trends

Apyx Medical's Short term Debt history runs 12 years deep, the most recent figure standing at $8.9 million for Q2 2023.

Quarterly Short term Debt changed N/A year-over-year to $8.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $8.9 million (changed N/A YoY) and the FY2019 annual result came in at $140000.0, changed N/A from the prior year.
Short term Debt was $8.9 million for Q2 2023 at Apyx Medical, up from $8.8 million in the prior quarter.
Across five years, Short term Debt topped out at $8.9 million in Q2 2023 and bottomed at $140000.0 in Q4 2019.
A 3-year average of $3.0 million and a median of $140000.0 in 2019 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Apyx Medical	167.53 Mn	136.65 Mn	7.93 Mn

Download Data